EUVIMEDEUVIMED entdecken
Crossref

Harnessing Fragment Merging and Chain Extension Approaches for Designing Phthalimidoalkyl‐Arylidene Thiazolidinedione Hybrids: New Frontiers in Apoptosis‐Inducing Cancer Treatment

Saad Shaaban, Ayman Abo Elmaaty iD, Tarek A Yousef iD, Marwa Sharaky, Mohamed Alaa Mohamed, Mohamed Alaasar iD, Arwa Omar Al Khatib iD, Amal F Dawood, Fatema S Alatawi iD, Awatif M E Omran, Khadra B Alomari iD, Ahmed A Al-Karmalawy iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Saad Shaaban und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia. Hauptthemen laut MEDLINE: Apoptosis, Antineoplastic Agents, Thiazolidinediones, Drug Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: This study was supported by the Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Ar….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of novel phthalimidoalkyl‐arylidene thiazolidinedione hybrids ( 10a–e and 11a–e ) were designed and synthesized by the combination of the bioactive phthalimide and thiazolidinedione pharmacophores and connected via an ethyl or propyl linker. Additionally, selenocyanates ( 12 and 13 ) were synthesized via nucleophilic substitution using KSeCN in DMF. The novel phthalimide benzylidene thiazolidinedione hybrids ( 10a – e and 11a – e ) and phthalimide selenocyanates ( 12 and 13 ) were examined as apoptotic inducers against 15 cancer cell lines. Compound 10e showed the best mean growth inhibition percentage (GI%) of 64.60% compared with the FDA‐approved doxorubicin (Dox). Moreover, the synthesized compounds showed higher therapeutic efficacy against the A549 and MDA‐MB‐468 cell lines compared with HeLa and FaDu cells. Analogs 10e , 11b , 11d , and 13 displayed the highest cytotoxic potential at the MDA‐MB‐468 cancer cells with IC 50 values of 12.52, 13.16, 12.00, and 14.78 µM, respectively, in comparison to Dox (IC 50 = 11.39 µM). Evaluation of the apoptotic and proinflammatory markers after treatment with analog 13 revealed upregulation of the proapoptotic Caspases 3, 8, and 9 and downregulation of the prosurvival proteins BCL‐2, MMP2, and MMP9 by 1.27‐, 6.71‐, 2.00‐, 2.26‐, 2.31‐, and 2.12‐fold change, respectively. Furthermore, analog 13 showed the most significant downregulation of COX‐2 and IL‐1β protein expression, showing 2.08‐ and 2.34‐fold changes, respectively. Finally, the molecular docking study against Caspase 6 demonstrated eligible binding affinities of the examined analogs. Overall, this study demonstrated that the synthesized compounds are promising apoptotic inducers and possess great potential as anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisAntineoplastic AgentsThiazolidinedionesDrug DesignPhthalimidesNeoplasmsHumansStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular StructureCell Line, TumorMolecular Docking SimulationDose-Response Relationship, DrugCell Proliferation

Stichwörter der Autor:innen

apoptosiscaspaseschain extensionfragment mergingthiazolidinedione

Substanzen

Antineoplastic AgentsThiazolidinedionesPhthalimides

Autor:innen und Institutionen

  • Department of Chemistry, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Port Said University, Port Said, Egypt.
  • Medicinal Chemistry Department, Clinical Pharmacy Program, East Port Said National University, Port Said, Egypt.
  • College of Science, Chemistry Department, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Cancer Biology Department, Pharmacology Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
  • Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt.

ORCID-Profile: Ayman Abo Elmaaty, Tarek A Yousef, Mohamed Alaasar, Arwa Omar Al Khatib, Fatema S Alatawi, Khadra B Alomari, Ahmed A Al-Karmalawy

Förderung

  • This study was supported by the Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Ar…

Zitieren

APA

Shaaban, S., Elmaaty, A. A., Yousef, T. A., Sharaky, M., Mohamed, M. A., Alaasar, M., Khatib, A. O. A., Dawood, A. F., Alatawi, F. S., Omran, A. M. E., Alomari, K. B., & Al-Karmalawy, A. A. (2025). Harnessing Fragment Merging and Chain Extension Approaches for Designing Phthalimidoalkyl‐Arylidene Thiazolidinedione Hybrids: New Frontiers in Apoptosis‐Inducing Cancer Treatment. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70118

Vancouver

Shaaban S, Elmaaty AA, Yousef TA, Sharaky M, Mohamed MA, Alaasar M, et al. Harnessing Fragment Merging and Chain Extension Approaches for Designing Phthalimidoalkyl‐Arylidene Thiazolidinedione Hybrids: New Frontiers in Apoptosis‐Inducing Cancer Treatment. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70118

BibTeX
@article{Shaaban2025,
  author = {Shaaban, Saad and Elmaaty, Ayman Abo and Yousef, Tarek A and Sharaky, Marwa and Mohamed, Mohamed Alaa and Alaasar, Mohamed and Khatib, Arwa Omar Al and Dawood, Amal F and Alatawi, Fatema S and Omran, Awatif M E and Alomari, Khadra B and Al-Karmalawy, Ahmed A},
  title = {Harnessing Fragment Merging and Chain Extension Approaches for Designing Phthalimidoalkyl‐Arylidene Thiazolidinedione Hybrids: New Frontiers in Apoptosis‐Inducing Cancer Treatment},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70118}
}
Kostenlos starten →